Form 4: Immunocore Holdings Director Herbst Acquires Share Options

Director Roy Steven Herbst acquired share options in Immunocore Holdings plc on May 23, 2024.

Summary

• Roy Steven Herbst, a director of Immunocore Holdings plc, acquired share options on May 23, 2024.
• The transaction involved the acquisition of 14,534 share options with an exercise price of $50.47.
• These options vest at the earlier of May 23, 2025, or the day before the next annual general meeting, contingent upon continuous service.
• Following the transaction, Herbst directly owns 14,534 share options.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction. The acquisition of share options by a director can be seen as a positive sign, but it's a routine event.

Positives

• The acquisition of share options by a director signals confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors and their alignment with shareholder interests.

Comparison to Industry Standards

• Share option grants to directors are a common practice in the biotechnology industry to incentivize performance and align interests with shareholders.
• The vesting schedule and exercise price are typical for such grants, often tied to continued service and market value at the time of the grant.
• Comparable companies like Amgen, Gilead, and Regeneron also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The acquisition of share options by a director can positively influence shareholder confidence.

Key Dates